Propylthiouracil
As of the edition of 20 October 2026, Propylthiouracil is a small molecule: marketed, first approved in 1982 (US); acts on DIO1 and TPO; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Propylex
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Curatis AG; 4 holders in all
- Registered trials
- 5, 0 stopped early
- Disease areas
- Hormones; Eye; Immune system; Heart and blood vessels; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| All trials | 5 |